161
Views
12
CrossRef citations to date
0
Altmetric
Theme: General - Reviews

Myxomatous mitral valve disease bench to bedside: LDL-density-pressure regulates Lrp5

 

Abstract

The myxomatous mitral valve is the most common form of valvular heart disease. The pathologic presentation of myxomatous mitral valve disease varies between valve thickness, degree of leaflet prolapse and the presence or absence of flail leaflets. Recent molecular biology studies have confirmed that the myxomatous changes in mitral valve prolapse equals a cartilage phenotype, which is regulated by the Lrp5 receptor. Clinically, echocardiography defines the valve pathology to determine the surgical approach to valve repair or replacement. Furthermore, the timing of surgical valve repair is controversial and is the subject of a current multicenter trial. The results will resolve the timing of whether watchful waiting versus early surgical valve repair decreases morbidity and mortality of this disease process. This review will summarize the current understanding of the cellular and hemodynamic mechanisms of myxomatous mitral valve disease, which may have future implications in the targeted therapy of this disease process.

Financial & competing interests disclosure

NM Rajamannan is the inventor on a patent for methods to slow progression of valvular heart disease. This patent is owned by the Mayo Clinic and the author does not receive any royalties from this patent. This work is supported by NIH grant funding: 5R01HL085591 and 3R01HL085591S1. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Key issues

  • The European Society of Cardiology and American College of Cardiology/American Heart Association valvular guidelines suggest two different timing to surgical valve repair, based on the presence and absence of symptoms. However, the long-term safety, morbidity and mortality data still remain to be firmly established, in part due to the need for more stringent risk stratification using valve pathology, hemodynamics and clinical symptoms.

  • A well-designed, adequately powered clinical surgical trial is ongoing to address these shortcomings and provide a more definitive assessment of the indications of timing to surgical valve repair.

  • Experimental studies indicate the potential for traditional cardiovascular risk factors in the development of myxomatous mitral valve disease; future epidemiologic studies testing this hypothesis are necessary to further define this hypothesis and the potential for targeting this disease with cholesterol-lowering medications and antihypertensive therapy.

Notes

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.